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Background: Yoga interventions offer promise for the treatment of major depressive disorder 
(MDD), yet their safety and potential impact on suicidal ideation (SI) have not been well 
documented. This study evaluated the safety of a randomized controlled dose-finding trial of 
Iyengar yoga plus coherent breathing for individuals with MDD, as well as the potential effects 
of the intervention on SI without intent.  
Methods: Participants with Beck Depression Inventory-II (BDI-II) scores ≥ 14 and a diagnosis 
of MDD (using DSM-IV criteria) were randomized to either a low dose group (LDG) or high 
dose group (HDG) and received a 12-week manualized intervention. The LDG included two 
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90-minute yoga classes plus three 30-minute homework sessions weekly. The HDG offered 
three 90-minute classes plus four 30-minute homework sessions weekly.  
Results: Thirty-two individuals with MDD were randomized, of which 30 completed the 
protocol. At screening, SI without intent was endorsed on the BDI-II by 9 participants; after 
completing the intervention, 8 out of 9 reported resolution of SI. There were 17 adverse events 
possibly-related and 15 definitely-related to the intervention. The most common protocol-
related adverse event was musculoskeletal pain, which resolved over the course of the study.  
Conclusions: The Iyengar yoga plus coherent breathing intervention was associated with the 
resolution of SI in 8 out of 9 participants, with mild side effects that were primarily 
musculoskeletal in nature. This preliminary evidence suggests that this intervention may 
reduce SI without intent and be safe for use in those with MDD. 
 
INTRODUCTION 
Major depressive disorder (MDD) is a common, recurrent, often chronic and disabling disorder(1). 
Depression is globally responsible for more years lost to disability than any other disease(2). Up to 40% 
of individuals with MDD treated with antidepressant medication do not achieve full remission(3). 
Moreover, residual symptoms of depression are associated with increased risk of recurrence and 
relapse(4). Data from randomized controlled trials (RCTs) indicate that yoga holds promise as an 
effective intervention for the treatment of depression(5–8). However, the safety of yoga, including effects 
on suicidal ideation (SI), have not been well studied in individuals with MDD.  
A meta-analysis and review of 12 RCTs (N=619) using yoga for the treatment of depression 
found that yoga was significantly better than usual care, relaxation exercises, and aerobic exercise. 
However, this same review noted that there were no published reports of safety data from RCTs. In a 
recent meta-analysis of 92 RCTs across a broad range of conditions, yoga was not associated with 
increased frequency of intervention-related non-serious or serious adverse events compared to 
exercise or usual care. However, when compared to non-physical interventions, such as psychological 
or educational interventions, yoga was associated with increased frequency of intervention related non-
serious adverse events; serious adverse events were rare(5). There is a need for specific safety data for 
yoga-based interventions in MDD.  
There are no known studies evaluating the use of an Iyengar yoga and coherent breathing 
intervention (yoga intervention) for SI. This manuscript presents a follow-up analysis of an RCT of a 12-
week yoga intervention for individuals with MDD. The primary study found that both the low dose group 
(LDG; 2x weekly + homework) and high dose group (HDG; 3x weekly + homework) were associated 
with decreased Beck Depression Inventory-II (BDI-II) scores consistent with response (50% reduction 
in BDI-II scores) and remission (BDI-II < 14)(9). This manuscript has two aims: 1) to evaluate the effects 
of the intervention on SI without intent in participants with MDD, and 2) to assess the safety of the 
intervention. Musculoskeletal AEs were anticipated based on previous reports(10,11).  
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MATERIALS AND METHODS 
We present SI data and safety findings from a parent study described in a previous report(9), conducted 
October 2013 - September 2015 at the Boston University Medical Center (BUMC), and approved by 
their Institutional Review Board (IRB). Recruitment was conducted in the community with flyers, 
newspaper advertisements, and the internet. Baseline data were collected prior to randomization. A 
rolling admissions design was utilized; participants entered the 12-week intervention to which they were 
randomized using a permuted block design (n=4). A blinded statistician (with no participant contact) 
placed group assignments in sealed envelopes, sequentially opened when a participant was 
randomized.  
 
Intervention: Participants were randomized to either a LDG or a HDG. The LDG was assigned  
two 90-minute classes and three 30-minute homework sessions per week. The HDG was  
assigned three 90-minute classes and four 30-minute homework sessions per week. 
Homework consisted of 15-minutes of Iyengar yoga followed by 15-minutes of coherent  
breathing. Each 90-minute class included approximately 60-minutes of Iyengar yoga postures,  
10-minutes of transition including deep relaxation, and 20-minutes of coherent breathing, 
paced by a chime tone recording on a compact disc. Iyengar yoga emphasizes correct  
alignment while performing postures. Coherent breathing entails breathing through the nose 
with equal duration of inhalation and exhalation at a rate of 5 breaths per minute. These  
practices have been shown to optimize heart rate variability (HRV) and sympatho-vagal  
balance(12–14). Further details of this same intervention were previously reported(9).  
 
Instructor Training and Intervention Fidelity: All instructors completed an Iyengar Introductory Level II 
certification exam (≥ 2 years of study), had >5 years teaching experience, used the intervention 
manual, received training in coherent breathing, were assessed quarterly by the Principal Investigator 
(PI) using a protocol compliance fidelity instrument. There were 15 fidelity assessments on 5 instructors 
that documented fidelity to the assessment categories. Instructors were trained and allowed to modify 
the sessions to meet the needs of the participants, which included the use of props (e.g., blocks, 
blankets, and straps). The protocol encouraged instructors to modify the classic postures such that 
participants could be successful in their attempts while also minimizing injuries.  
 
Instruments: The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) was used at 
screening to confirm the diagnosis of MDD and assess for other Axis I disorders(15). The Beck 
Depression Inventory-II (BDI-II), a 21-item, self-rated questionnaire, measured depressive 
symptoms(16). Scoring criteria: minimal depression 0-13, mild depression 14-19, moderate depression 
20-28, and severe depression 29-63. BDI-II question #9 assessed SI with the following response 
options: 0) I don’t have any thoughts of killing myself; 1) I have thoughts of killing myself, but I would 
not carry them out; 2) I would like to kill myself; and 3) I would kill myself if I had the chance.  
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-administered 
assessment(17). At screening, the C-SSRS form was used for two time frames: 1) “lifetime”, and 2) “last 
year” (rather than the standard time frame of “past month”). At weeks 4, 8, and 12, a “since the last 
visit” time frame was used. The C-SSRS SI section uses the following items: 1) wish to be dead, “Have 
you wished you were dead or wished you could go to sleep and not wake up?”; 2) non-specific active 
suicidal thoughts, “Have you actually had any thoughts of killing yourself?”; 3) active suicidal ideation 
with any method (not plan) without intent to act, ”Have you been thinking about how you might do 
this?”; 4) active suicidal ideation with some intent to act; without specific plan; and 5) active suicidal 
ideation with specific plan and intent. Affirmative answers to items 4 or 5 during screening were 
exclusionary.  
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The Weekly Safety Form contained the following questions: 1) “Are you feeling more 
depressed?”; 2) “Are you feeling suicidal?”; 3) “Mark your level of depression in the last week – 
response options: none, mild, moderate, severe”; 4) “Have you had any muscle soreness?”; and 5) 
“Have you had any other adverse events this week? (Adverse events are new or worsening medical 
problems.) If so, please list them.” Participants returned completed Weekly Safety Forms at the 
beginning of each calendar week of the intervention. As the 12-week intervention could occur over 13 
calendar weeks, each participant could complete a maximum of 13 Weekly Safety Forms.  
Clinical evaluations by a psychiatrist (PI) at baseline and a psychiatrist (PI) or clinical 
psychologist at weeks 4, 8, and 12 included a review of Weekly Safety Forms, BDI-II, and C-SSRS. 
Additional clinical assessments by a psychiatrist or clinical psychologist were triggered by any 4-point 
increase on BDI-II, worsening depression or suicidality on the Weekly Safety Forms, staff observations 
of participant distress, or participant reports of distress. The BDI-II was only given during assessment 
visits, when the participant also had a clinical and safety assessment. Adverse events (AEs) were 
defined as new or worsening medical problems that increased by one level of severity. Severity level of 
AEs was rated: 1) mild - does not have a major impact on the participant, 2) moderate - causes some 
minor inconveniences, and 3) severe - causes substantial disruption to the participant. Adverse event 
relationship to study was rated: 1) definitely-related, 2) possibly-related, and 3) not related. Pre-existing 
conditions that continued in the pre-existing pattern were not considered AEs. All subjects had 
depression at baseline, and depression was not reported as an AE unless a patient changed one level 
of AE severity rating from their pre-existing baseline condition. Severity of AE and relationship to study 
was determined by the study PI, a board-certified psychiatrist and neurologist.  
 
Original Inclusion and Exclusion Criteria: Participants met the following criteria: 18 to 55 years of age, 
current SCID diagnosis of MDD, and at least mild depression based on BDI-II total score of 14-27 (≥ 28 
indicates severe depression). Co-morbid anxiety disorders that would not interfere with study 
participation were allowed. The following items were exclusionary: treatment with antidepressants; 
psychotherapy for depression within 3 months of screening; more than 6 one-hour sessions of mind-
body practices in the last 6 months; current prayer practice (>2 hours per week), as this could be 
similar to meditation; diagnosis of bipolar illness or psychosis; lifetime history of a suicide attempt or SI 
with or without intent within the last year (using C-SSRS criteria); current alcohol or substance abuse or 
dependence; and inability to complete the study protocol.  
 
Adjusted Inclusion and Exclusion Criteria: After the enrollment of 16 of the 32 participants, the inclusion 
and exclusion criteria were liberalized because no serious AEs were observed, and individuals who 
could potentially safely benefit from the intervention were being excluded by restrictive eligibility criteria. 
The inclusion criteria were expanded to: 1) remove the BDI-II total score upper limit (<28) to include 
individuals with more severe depressive symptoms; 2) increase the age limit from 55 to 65; and 3) 
include participants on stable doses of antidepressant medications for at least three months with no 
anticipated dosage change during the study. Exclusion criteria were expanded to allow SI without 
intent, while still excluding SI with intent within the past year. This particular exclusion criterion was 
liberalized consistent with  the 2008-2012 US National Survey on Drug Use and Health, that found 
past-month suicide attempts were far less common in those adults reporting SI without a plan in the 
past 12-months compared to those who reported SI with a plan (3.7% to 37.0%, respectively)(18).  
 
Statistical Methods: Study data were collected using Research Electronic Data Capture (REDCap). 
Data were analyzed using SPSS version 24. P values for all statistical tests were two-tailed, using an 
alpha of .05 for statistical significance, unless otherwise noted. Pearson Chi-Square tests were used to 
compare LDG and HDG across categorical variables, such as SI vs. no SI, race, ethnicity, and gender. 
Independent-Samples T-Tests were conducted to compare continuous demographic variables (e.g., 
age). If Levene’s Test for the Equality of Variances was violated, the degrees of freedom and p-values 
were reported for equal variances not assumed and noted as such. Bivariate correlations were used to 
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explore the relationship between total numbers of adverse events and age. AEs were not compared 
between the LDG and HDG, because there were multiple AEs within participants, such that a discrete 
denominator for the appropriate statistical test (i.e., generalized linear model [binomial model] allowing 
multiple events within a single subject) could not be calculated.  
 
RESULTS 
Telephone screening yielded 265 participants; 86 participated in a screening visit, 32 were randomized, 
and 30 completed the intervention (LDG: n=15; HDG: n=15). Subject flow chart was previously 
provided(9). Only adverse events in participants who were randomized were reported. Two participants 
(1 per arm) were lost to follow-up prior to the week-4 evaluation; they did not complete a BDI-II or C-
SSRS after screening and were not included in the analyses.  
 
Baseline Demographics and Yoga Dose: There were no statistically significant differences in baseline 
demographics (See Table 1). As reported in the primary manuscript(9), compliance with total assigned 
class and homework minutes did not differ between groups (p=0.77): LDG 84% ± 19% and HDG 87% ± 
28%. As expected, the HDG had significantly greater total (in class + homework time) yoga minutes 
(4,075±1,314) compared to the LDG (2,737±625; p<0.001).  
 



















*Violated Levene’s Test for Equality of Variances, reported for unequal variances.  
** Could not complete statistical test due to zero participants per group.  
LDG: Low Dose Group (two 90-minute yoga classes plus three 30-minute homework sessions weekly) 
HDG: High Dose Group (three 90-minute classes plus four 30-minute homework sessions weekly) 
 
 
This report focuses on AEs possibly- or definitely-related to the protocol. There were 17 individuals 
responsible for the 32 possibly- or definitely-related mild AEs (See Table 2). The most common study 
related AE, musculoskeletal pain, was anticipated and resolved during the study. Musculoskeletal pain 
was reported in 16 out of 30 (53%) of participants: 12 reports were possibly-related and 13 were 
definitely-related to the intervention. Table 2 provides a list of the participants who accounted for the 
related AEs. Other than musculoskeletal pain, AEs possibly-related to the intervention included 
Demographic LDG (n=15) 
HDG 
(n=15) t-test or χ
2 p-value 
Age (years) 34.7 + 10.4 38.4 + 15.1 t (24.84) = -0.79* 0.44 
Gender 
(female/male) 12/3 13/2 χ
2(1) = 0.24 0.62 
Years of 
Education 16.7 + 2.2 16.3 + 2.2 t (28) = 0.51 0.62 
Ethnicity   **n/a **n/a 
Hispanic 0/15 0/15   
Race   χ2(2) = 3.40 0.18 
Caucasian 13/15 10/15   
African 
American 2/15 2/15   
Asian 0/15 3/15   
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headaches, dizziness, and a nose bleed. One participant reported headaches when classes were held 
in a room with a carpet. One participant had a nose bleed that did not require medical intervention, 
which was likely an exacerbation of an existing condition due to inversions . Definitely-related AEs other 
than musculoskeletal pain, included a headache and increased negative/ruminative thoughts 
associated with use of the at home coherent breathing CD. The homework protocol was modified for 
this participant to include 30-minutes of postures without breathing exercises, which resolved the 
ruminative thoughts.  
 
Table 2: Adverse events (AEs) possibly- and definitely-related to the study intervention 




1 1 Low Musculoskeletal Pain Calf   
2 1 Low Musculoskeletal Pain Left hip   
3 1 Low Musculoskeletal Pain Midback   
4 1 Low Musculoskeletal Pain Low back   
5 2 Low Musculoskeletal Pain Low back & left groin   
6 2 Low Musculoskeletal Pain Right shoulder   
7 2 Low Musculoskeletal Pain Right groin   
8 3 High Musculoskeletal Pain Neck   
9 3 High Musculoskeletal Pain General   
10 4 High Musculoskeletal Pain Left hip   
11 5 High Musculoskeletal Pain Low back   
12 6 High Musculoskeletal Pain Neck   
13 7 Low     Headache 
14 7 Low     Headache 
15 7 Low     Headache 
16 1 Low     Dizziness 
17 8 High     Nose bleed 
Definitely-Related 
18 9 Low Musculoskeletal Pain Low back    
19 9 Low Musculoskeletal Pain Low back    
20 9 Low Musculoskeletal Pain Low back    
21 10 Low Musculoskeletal Pain General   
22 10 Low Musculoskeletal Pain General   
23 11 Low Musculoskeletal Pain Arm   
24 8 High Musculoskeletal Pain Low back   
25 12 High Musculoskeletal Pain General   
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26 13 High Musculoskeletal Pain Ankle   
27 14 Low Musculoskeletal Pain General   
28 15 High Musculoskeletal Pain 
Arms and 
Hamstrings   
29 16 Low Musculoskeletal Pain Hamstrings   
30 17 High Musculoskeletal Pain Low back    
31 5 High     
↑ Negative 
thoughts 
32 5 High     Headache 
 
Out of a possible maximum of 390 Weekly Safety Forms (30 participants completing up to 13 forms 
each), 366 (94%) were collected. The missing 6% occurred because some participants completed only 
12 forms or did not turn in all scheduled forms. Twenty-three reports of worsening depression were 
identified by the Weekly Safety Forms (“Are you feeling more depressed?”). Thirteen individuals were 
responsible for the 23 reports of worsening depression. No subjects had an increase in the severity 
level of their depressive symptoms using AE criteria. Accordingly, none of the problem endorsements of 
worsening depression on the Weekly Safety forms were considered AEs based on the severity level of 
AEs (defined in the Method Section). No evaluations found increased risk of self-harm, or worsening 
functional impairment. No participants were withdrawn or referred for conventional treatment during the 
study. 
 
Reports of SI: 
BDI-II: BDI-II question #9, item 1 (I have thoughts of killing myself, but I would not carry them out) was 
endorsed by 9 participants at screening (4 LDG, 5 HDG), 4 at week-4 (2 LDG, 2 HDG), 1 at week-8 (1 
HDG), and 1 at week-12 (1 HDG). At week-4, 1 participant (1 HDG) endorsed item 2 (I would like to kill 
myself). This person was evaluated and found to have SI without intent (See Figure 1). Pearson Chi-
Square revealed no differences at screen between the LDG and HDG on BDI-II item #9 zero versus 
non-zero responses (X2(1)=.159, p=0.690).  
  
Figure 1: Comparative number of participants endorsing suicidal ideation on Question #9 items 1 and 2 of the 




Legend: BDI-II question #9 assessed suicidal ideation severity:  
Item 1) I have thoughts of killing myself, but I would not carry them out;   
Item 2) I would like to kill myself. 
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Legend: 1) wish to be dead; item 2) non-specific active suicidal thoughts; item 3) active suicidal ideation with any 
method (not plan) without intent to act.  
Note: The total number of participants endorsing suicidality at each time point is equal to the total number for item 
1. All participants who endorsed item 2 also endorsed item 1; all participants who endorsed item 3 also endorsed 
items 1 and 2. 
 
C-SSRS: The C-SSRS item 1 (passive SI) was endorsed by 10 participants at screening (5 LDG, 5 
HDG), 5 at week-4 (1 LDG, 4 HDG), 2 at week-8 (2 HDG), and 1 at week-12 (1 HDG). Item 2 (SI 
without intent) was endorsed by 5 participants at screening (3 LDG; 2 HDG), 2 at week-4 (2 HDG), 1 at 
week-8 (1 HDG), and 0 at week 12. Item 3 (SI with any method without intent to act) was endorsed by 2 
participants at screening (2 HDG). Participants who endorsed items greater than 1 also endorsed lower 
item numbers as well, therefore the total number of participants reporting SI in any form equals the 
number of participants endorsing item 1 (See Figure 2). Pearson Chi-Square revealed no differences 
between the LDG and HDG at screen on C-SSRS passive SI responses (within the past year) when 
comparing zero versus non-zero responses (X2(1)=.000, p=1.000). 
 





Legend: 1) wish to be dead; item 2) non-specific active suicidal thoughts; item 3) active suicidal ideation with any 
method (not plan) without intent to act.  
Note: The total number of participants endorsing suicidality at each time point is equal to the total number for item 
1. All participants who endorsed item 2 also endorsed item 1; all participants who endorsed item 3 also endorsed 
items 1 and 2. 
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One participant at screening and one at week-8 endorsed SI on the CSSR-S but not on the BDI-II. The 
CSSR-S at screen covered a longer time frame (“within the last year”) compared to the BDI-II (two-
weeks). Also, the BDI-II only evaluated thoughts of killing oneself, whereas the CSSR-S has a more 




This study evaluated changes in SI without intent and overall safety of a LDG and HDG 12-week yoga 
intervention for adults with MDD. As reported previously, the intervention was associated with 
significantly decreased BDI-II total scores, demonstrating large effect sizes for both the LDG (Cohen’s d 
= -1.89) and HDG (Cohen’s d = -2.81) with a significant correlation in the expected direction between 
total number of yoga minutes and decreases on the BDI-II total score(9). Overall, SI resolved in all but 
one participant and the intervention appeared to be tolerable, with musculoskeletal pain being the most 
common AE, which resolved and was mild in nature. There were no serious adverse events related to 
the protocol, nor did any subject need to be hospitalized or removed from the protocol due to worsening 
depressive symptoms or SI.  
 
Suicidal Ideation: Intervention participation was associated with decreases in SI for 8 of the 9 
participants who reported SI without intent at screening. Out of the 30 participants, only one reported a 
transient increase in rating of SI at week 4 (Figure 1). Decreased depressive symptoms and resolution 
of suicidality were seen in all but one participant (HDG) who continued to endorse SI on BDI-II and C-
SSRS at week-12, while showing a decrease in BDI-II total score from 36 (severe depression) to 15 
(mild depression).  
 
While there is an assumed relationship between depressive symptoms and the presence of SI, there is 
a need for explicit evaluations of the effect of treatments on SI(19). A systematic review and meta-
analysis of RCTs in patients with MDD treated with serotonin selective reuptake inhibitors (SSRIs), with 
a secondary outcome measures of suicide, suicide attempts, and SI did not find a significant 
differences between participants randomized to placebo versus a SSRI for suicide (6 RCTs), suicide 
attempts (8 RCTs) or SI (11 RCTs)(20).  
The lack of compelling evidence that RCTs of SSRIs decrease suicide ideation is in contrast to the 
findings of this study. These promising results need replication, given that this is the only study, to date, 
documenting reductions in SI associated with a yoga-based intervention in an MDD population. 
 
Safety/Adverse Events: Safe and effective alternatives to antidepressant medications are sorely 
needed, given the significant AEs associated with antidepressant medications, such as: 1) the potential 
for the exacerbation of suicidality(21,22); 2) the induction of agitated and/or mixed manic and 
depressive states(23); 3) the burdensome common side effects (e.g., weight gain, sexual dysfunction, 
fatigue)(24); and 4) the potential for medication misuse in suicide attempts. The purpose of this paper 
was to understand what kind of AEs are common in a yoga-based intervention for depression and 
whether these AEs would involve a clinician’s immediate attention or would cause worsening 
psychiatric symptomatology. AEs in this study were mild with no serious intervention-related AEs; none 
of which were present in this study. Based on the Weekly Safety Forms and clinician evaluations of 
adverse events at weeks 4, 8, and 12 and the two-week follow-up phone call, all AEs were mild and all 
but one possibly-related back pain resolved by the two-week follow-up. The most common AE, 
musculoskeletal pain, was anticipated. There did not appear to be differences in musculoskeletal pain 
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between the LDG or HDG (though we were not able to conduct statistical tests on these data; please 
see Method Section), consistent with previous reports of dosage not being a determining factor in 
increased adverse events in yoga trials(11). No participants dropped out of the study due to 
musculoskeletal pain or any other AEs. Results indicated that yoga seemed tolerable to this population 
of individuals with MDD and did not worsen suicidality or depression, but was associated with 
decreased SI and depressive symptoms.   
 
Strengths: Studies using yoga to treat depression have been limited by a lack of manualized yoga-
based protocols(25), treatment fidelity monitoring(25), and insufficient reporting of safety findings(6). 
This randomized dosing study used a manual-driven protocol that was first applied to healthy 
controls(10) and was then revised by the addition of the coherent breathing practice when tested in 
participants with MDD(9). The yoga instructors attended study meetings to ensure consistency of 
delivery, used the manual to conduct each class, and received quarterly compliance feedback from the 
PI(9). The teacher training and protocol policy of modifying yoga poses to a participant’s physical 
abilities could contribute to the infrequent occurrence and mild nature of study AEs. SI was measured 
by two validated and commonly used scales, the BDI-II and C-SSRS. Participants were monitored for 
safety by a psychiatrist or clinical psychologist throughout the study. The procedures to maintain 
fidelity, excute safety protocols, and capture AEs in this study were clearly documented.  
 
Limitations: The lack of a control group was a limitation, which should be addressed in future RCTs.  
The small sample size (N=30) limits generalizability. Physical fitness was not evaluated prior to 
randomization such that the effect of physical fitness on AEs could not be evaluated. The findings 
cannot be generalized to individuals with more severe depression (BDI-II >40), SI with intent, or a 
history of suicide attempts within the past year. Finally, as with previously reported yoga studies(26,27), 
the majority of participants were white, educated females; future research would benefit from engaging 
more diverse populations.  
 
CONCLUSIONS 
In adults with MDD, a 12-week Iyengar yoga plus coherent breathing intervention was  
associated with robust reductions in depressive symptoms and SI without intent on the BDI-II 
suicide item and C-SSRS in both the LDG and HDG. The intervention had a mild side effect  
profile, good tolerability, and a high level of adherence. The most common AE was  
musculoskeletal pain. This study provides preliminary data concerning the safety and efficacy  
of for yoga-based interventions as a potential treatment for individuals with MDD and SI  
without intent. However, larger RCTs with a longer duration are indicated to validate and 
extend these preliminary findings.  
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